Clinical trials: HPV InfectioN
HPV Infections
V501 Efficacy Study in Women Aged 18 to 26 (V501-027)
A study to evaluate the efficacy, immunogenicity, safety and tolerability of V501 in adult women
- Trial name
- NCT00378560
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- Volunteers
- 1,021 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Cancer, Genital Warts
Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)
The purpose of the study is to determine if an investigational vaccine with a single component develops an immune response that is similar to the equivalent investigational vaccine with four components to reduce cervical disease.
- Trial name
- NCT00092482
- Testing
- V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine / Duration of Treatment: 4 years
- Volunteers
- 3,882 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Genital Warts
Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053)
This study is designed to demonstrate non-inferior immunogenicity of 3 doses of the 9-Valent Human Papillomavirus (9vHPV) vaccine (GARDASIL™9, V503) in Chinese males 9 through 19 years of age, and 2 doses of the 9vHPV vaccine in…
- Trial name
- NCT05314023
- Testing
- 9vHPV vaccine
- Where
- 5 sites in China
- Volunteers
- 1,590 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Papillomavirus Infection, Cervical Intraepithelial Neoplasia
Long-Term Immune Persistence After Bivalent HPV Vaccination in Females From Study 311-HPV-1005
This is a single-center, open-label, prospective observational extension of Study 311-HPV-1005 (NCT04965350). The study follows females who received at least one dose of a bivalent human papillomavirus vaccine containing HPV-16…
- Trial name
- NCT07833852
- Testing
- Recombinant Human Papillomavirus Bivalent (Types 16 and 18) Vaccine (Pichia pastoris)
- Where
- China
- Volunteers
- 486 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
Head and Neck Cancer, Cervical Cancer
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived engeneered T cells are engineered to express a T cell receptor that recognizes cancer-associated antigens…
- Conditions
- Head and Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma, Melanoma
- Trial name
- NCT05973487
- Testing
- TSC-204-A0201, TSC-204-C0702, TSC-200-A0201
- Where
- 21 sites in United States
- Volunteers
- 840 people
- Sponsor
- TScan Therapeutics, Inc.
Papillomavirus Infections
Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.
The purpose of this study was to evaluate efficacy of 851B gel over a range of concentrations and dosing regimens on high-risk cervical human papillomavirus infection in women.
- Trial name
- NCT00312286
- Testing
- 851B
- Where
- 93 sites in United States, Canada and 1 more
- Volunteers
- 538 people
- Sponsor
- Takeda
HPV InfectioN, HPV-Related Carcinoma
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years
A total of 18000 healthy women aged 18-45 years old were divided into three age groups: 18-26 years old, 27-35 years old, and 36-45 years old. The experimental group and the placebo group were randomly assigned in a ratio of 1:1.
- Trial name
- NCT06041061
- Testing
- Recombinant 14-Valent Human Papillomavirus Vaccine（Insect Cell）
- Where
- 5 sites in China
- Volunteers
- 18,000 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Dengue Fever, Dengue Hemorrhagic Fever
Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix®
The aim of this study was to investigate the immunogenicity and safety of CYD dengue vaccine and Cervarix when administered concomitantly or sequentially in healthy female participants aged 9-14 years of age.
- Conditions
- Dengue Fever, Dengue Hemorrhagic Fever, Human Papillomavirus Disease
- Trial name
- NCT02979535
- Testing
- CYD Dengue Vaccine, Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant
- Where
- Mexico
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Infections, Papillomavirus
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
This phase 3b study is designed to assess the safety of GlaxoSmithKline Biological's HPV vaccine GSK580299 in female subjects who took part in study 580299/008 and received the control vaccine (Hepatitis A vaccine).
- Trial name
- NCT00799825
- Testing
- GSK Biological's HPV vaccine GSK580299 (Cervarix™)
- Where
- 48 sites in United States, Canada
- Volunteers
- 346 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HPV 16 Infection
Study of Human Papillomavirus (HPV) 16 Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females (V501-005)
Subjects received HPV 16 L1 VLP vaccine or placebo (1:1 ratio). Endpoints included efficacy, immunogenicity, and safety.
- Trial name
- NCT00365378
- Testing
- Comparator: HPV 16 L1 Vaccine
- Volunteers
- 2,409 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Anogenital Human Papilloma Virus Infection, Condyloma Acuminata
Efficacy and Tolerability Study of V501 in Japanese Males (V501-122)
A study to evaluate the efficacy and tolerability of V501 (quadrivalent Human Papilloma Virus [HPV] [Type 6, 11, 16 and 18] L1 Virus-Like Particle vaccine, GARDASIL™) in healthy, 16- to 26-year old Japanese males.
- Trial name
- NCT01862874
- Testing
- V501
- Volunteers
- 1,124 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Common Warts
A Study of A-101 Solution in Subjects With Common Warts.
This is a randomized, double-blind, vehicle-controlled, parallel-group study with 3 treatment groups.
- Trial name
- NCT02669862
- Testing
- A-101 Solution 40, A-101 Solution 45, Vehicle Solution
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Aclaris Therapeutics, Inc.
Meningococcal Meningitis, Human Papillomavirus Infection
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents
This study will evaluate the safety and immune response of the Novartis Meningococcal ACWY conjugate vaccine when administered with Tdap and HPV vaccinations to healthy adolescents
- Conditions
- Meningococcal Meningitis, Human Papillomavirus Infection, Pertussis, Tetanus
- Trial name
- NCT00518180
- Testing
- Novartis Meningococcal ACWY Conjugate Vaccine, Tdap Vaccine
- Where
- Costa Rica
- Volunteers
- 1,620 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Anal High Grade Squamous Intraepithelial Lesion, Anal Precancerous Condition
Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL
This is a phase II double blind, placebo-controlled, randomized study of Artesunate suppositories for the treatment of HIV-negative men and women who have anal high grade squamous intraepithelial lesions (anal HSIL)
- Conditions
- Anal High Grade Squamous Intraepithelial Lesion, Anal Precancerous Condition, AIN 2/3, HPV Infection
- Trial name
- anal HSIL HIV- (NCT05555862)
- Testing
- Artesunate
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Frantz Viral Therapeutics, LLC
Human Papilloma Virus Infection, Human Papilloma Virus
Clinical Trial to Explore the Papilocare Gel Efficacy to Repair the Cervico-vaginal Mucosa With Lesions Caused by HPV
Phase II, exploratory, randomized, open, controlled and parallel groups clinical trial to evaluate the effectiveness of exploratory gel Papilocare in the repair of the cervico-vaginal mucosa with lesions caused by HPV.
- Conditions
- Human Papilloma Virus Infection, Human Papilloma Virus, Cervix Lesion
- Trial name
- PALOMA (NCT04002154)
- Testing
- Papilocare vaginal gel
- Where
- 9 sites in Spain
- Volunteers
- 134 people
- Sponsor
- Procare Health Iberia S.L.
Infections, Papillomavirus
Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected Females
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. The current study is designed to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' HPV vaccine…
- Trial name
- NCT00586339
- Testing
- Cervarix
- Where
- South Africa
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cervical Cancer, Genital Warts
Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)
The primary purpose of the study is to determine if GARDASIL (V501) with four components is able to prevent cervical cancer, cervical dysplasia, including Cervical Intraepithelial Neoplasia (CIN)(Any Grade) and Adenocarcinoma In…
- Trial name
- NCT00092521
- Testing
- V501, Human Papillomavirus (HPV) 16 Monovalent
- Volunteers
- 5,759 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Warts
The Purpose of This Study is to Determine Whether Topical Application of PEP005 is Safe for the Treatment of Common Wart(s)
Verruca vulgaris, otherwise known as the common wart, is caused by the human papillomavirus (HPV). Common warts are generally located on the hands and feet, but can also occur elsewhere (e.g., any areas of frequent contact).
- Trial name
- NCT00546611
- Testing
- PEP005
- Where
- Australia
- Sponsor
- Peplin
CIN 2/3, HPV Infection
Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)
This is a phase II double blind, placebo-controlled, randomized study of Artesunate vaginal inserts for the treatment of women who have cervical high grade intraepithelial neoplasia (CIN2/3).
- Conditions
- CIN 2/3, HPV Infection, Pre-Cancerous Dysplasia, Cervical Dysplasia
- Trial name
- ART-CIN_IIB (NCT04098744)
- Testing
- Artesunate vaginal insert
- Where
- 7 sites in United States
- Volunteers
- 78 people
- Sponsor
- Frantz Viral Therapeutics, LLC
Infections, Papillomavirus
A Single Centre Study to Evaluate the Safety and Immunogenicity of the Human Papillomavirus Vaccine (GSK-580299) in Chinese Females
A phase I, open label, single-centre study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' HPV -16/18 L1 VLP AS04 vaccine (GSK 580299, Cervarix TM), administered intramuscularly according to a 0, 1…
- Trial name
- NCT00549900
- Testing
- GSK580299 (Cervarix™ , HPV -16/18 L1 VLP AS04 vaccine)
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline